CVRx to Present at the William Blair 46th Annual Growth Stock Conference
Rhea-AI Summary
CVRx (NASDAQ: CVRX) announced that its management team will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026, at 10:40 a.m. CT. A live webcast and limited-time archived replay will be available at ir.cvrx.com.
Positive
- None.
Negative
- None.
News Market Reaction – CVRX
In the May 21 session, CVRX gained 0.17%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | Coverage policy update | Positive | +10.0% | Humana Medicare Advantage coverage policy for Barostim therapy announced. |
| May 11 | Quarterly earnings | Positive | -23.8% | Q1 2026 revenue growth and margin expansion with maintained guidance. |
| May 04 | Clinical trial update | Positive | -3.8% | First patient enrolled in large BENEFIT-HF heart failure trial for Barostim. |
| Apr 27 | Earnings call notice | Neutral | -2.2% | Announcement of date and time for Q1 2026 results and webcast. |
| Apr 20 | Board nomination | Positive | +5.0% | Nomination of Michael Dale to board, emphasizing Barostim commercial expertise. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive fundamental or strategic news has sometimes seen mixed or even negative next-day price reactions.
Over the past month, CVRX has reported several key developments. On May 11, 2026, it delivered Q1 results with 20% revenue growth and higher gross margin, yet the stock fell nearly 24%. Earlier, the first BENEFIT-HF patient enrollment and a Humana Medicare Advantage coverage policy for Barostim highlighted clinical and reimbursement momentum. Governance and communication have been active too, with a board nomination and scheduled earnings call. Today’s conference presentation fits into this ongoing effort to increase visibility and support Barostim adoption.
Key Terms
neuromodulation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026. The Company's presentation will begin at 10:40 a.m. (CT).
A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.
Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
